In DLBCL, TP53 mutations and copy number losses (CNLs) occur in approximately 20–30% of cases and correlate with aggressive clinical behavior, poor response to standard therapies (e.g., R-CHOP), and inferior overall survival [5,6,7,8,9,10]. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.